Renal Cancer Vaccines
It is estimated that approx 30,000 new cases of renal cell carcinoma (RCC) were diagnosed in 2002 (1). Approximately 20–30% of patients with RCC present with metastatic disease and their overall median survival is 6–8 mo (2). Although, metastatic RCC carries a poor prognosis, in a small subset of patients the disease has a variable course (3). Oliver et al. observed 73 patients with metastatic RCC without treatment (4). In this series, 4% had complete and spontaneous regression of disease and 3% had partial regression of disease. Furthermore, 5% had stable disease with no evidence of progression for more than 12 mo. There are also numerous cases of patients who recur with metastatic RCC over 10 yr after undergoing a nephrectomy for apparently localized disease. It is presumed from these observations that the immune system plays a key role in cases of spontaneous regression and durable remissions of RCC.
KeywordsEpidermal Growth Factor Receptor Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Autologous Tumor Autologous Tumor Cell
Unable to display preview. Download preview PDF.
- 6.Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3(Suppl 1):S70-S72.Google Scholar
- 16.Figlin R, Belldegrun A, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002:Abstract 35.Google Scholar
- 23.Gitlitz B, Figlin R, Kiertscher S, Moldawer N, Rosen F, Roth MD. A phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for cancer. J Immunother 2003, in press.Google Scholar
- 25.Gitlitz B, Belldegrun A, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma, submitted 2003.Google Scholar
- 35.Amato RJ, Murray L, Wood L, Savary C, Tomasovic S, Reitsma D. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex 96 (HSPP-96) vaccine. Proc Am Soc Clin Oncol 1999:Abstract.Google Scholar
- 39.Meyers ML, Minasian L, Motzer RJ, et al. Immunization with HLA-A2 matched allogeneic tumor cells that secrete interleukin-2 of (IL-2) patients with metastatic melanoma or metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1997:Abstract 441.Google Scholar
- 51.Finke JH, Rayman P, George R, et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res 2001; 7:940s–946s.Google Scholar
- 53.Rayman P, Uzzo RG, Kolenko V, et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J Sci Am 2000; 6(Suppl 1):581-S87.Google Scholar